108749-08-2

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE
• Synonyms: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE;2,7-Naphthyridine,1,2,3,4-tetrahydro-(9CI);2,7-Naphthyridine, 1,2,3,4-tetrahydro;1,2,3,4-Tetrahydro-2,7-naphthyridine ,95%
• CAS NO: 108749-08-2
• Molecular Formula: C₈H₁₀N₂
• Molecular Weight: 134.1784
• Product Categories: PYRIDINE
• Mol File: 108749-08-2.mol

Chemical Properties

• Melting Point: 248-250 °C(Solv: water (7732-18-5))
• Boiling Point: 244.473 °C at 760 mmHg
• Flash Point: 101.654 °C
• Appearance: /
• Density: 1.069 g/cm³
• Vapor Pressure: 0.0303mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.93±0.20(Predicted)
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(108749-08-2)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE(108749-08-2)

Safety Data

• Hazardous Substances Data: 108749-08-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-Tetrahydro-[2,7]naphthyridine is used as a building block for the synthesis of bioactive molecules and pharmaceutical drugs due to its versatile chemical structure and potential therapeutic properties.
Used in Medicinal Chemistry Research:
1,2,3,4-Tetrahydro-[2,7]naphthyridine is utilized as a valuable tool in medicinal chemistry research to explore its potential in the development of new drugs and therapeutic agents.
Used in Cancer Treatment:
1,2,3,4-Tetrahydro-[2,7]naphthyridine is employed as a therapeutic agent for the treatment of various types of cancer, leveraging its potential to interact with biological targets and modulate disease pathways.
Used in Infectious Disease Treatment:
1,2,3,4-TETRAHYDRO-[2,7]NAPHTHYRIDINE is also used in the development of treatments for infectious diseases, capitalizing on its ability to target specific biological processes and potentially inhibit the progression of these diseases.

InChI:InChI=1/C8H10N2/c1-3-9-5-8-6-10-4-2-7(1)8/h1,3,5,10H,2,4,6H2

Upstream product

• 42285-29-0 ethyl 2-(3-cyanopyridin-4-yl)acetate 
• 5444-01-9 3-cyano-4-methylpyridine 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 27224-97-1 1,3,6,8-tetrachloro-2,7-naphthyridine 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1380064-29-8 2,7-naphthyridine-1,3,6,8(2H,4H,5H,7H)-tetraone 
• 253-45-2 [2,7]naphthyridine 

Downstream Products

• 885270-18-8 tert-butyl octahydro-2,7-naphthyridine-2(1H)-carboxylate 
• 1438084-34-4 tert-butyl 7-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-quinazolin-6-yl)oxy)propyl)octahydro-2,7-naphthyridine-2(1H)-carboxylate 
• 1438073-74-5 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(octahydro-2,7-naphthyridin-2(1H)-yl)propoxy)quinazolin-4-amine 
• 1362159-43-0 C₂₂H₂₁N₃O₃S 

Relevant articles and documents

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Pyrrolidine-modified and 6-substituted analogs of nicotine: a structure-affinity investigation

Because the structural requirements for the binding of nicotine to central nicotine receptors remain largely uninvestigated, we undertook a systematic investigation of pyrrolidine ring-opened analogs.This led to a subsequent investigation of related conformationally restricted derivatives of these analogs.The results are reported relative to the binding of several well-known and widely used nicotine receptor ligands.Although none of the ring-opened analogs binds with higher affinity than (-)-nicotine (Ki = 2.3 nM), 3-(N-methyl-N-ethylaminomethyl)pyridine (12a; Ki = 28 nM) binds with significant affinity.A conformationally restricted analog of 12a, N-methyl naphthyridine 30b (Ki = 18 nM), binds with similar affinity. 6-Substitution of 12a and racemic nicotine seems to be tolerated when the substituent is halogen or methyl.In functional studies (hypolocomotion and antinociception in mice; stimulus generalization in nicotine-trained rats) 30b retains nicotine-like properties.Several of the 6-substituted compounds were 2 to 20 times more potent than (+/-)nicotine.Although the intact pyrrolidine ring of nicotine appears important for optimal affinity, its presence is not an absolute requirement for activity, and 6-position substitution of the pyridine nucleus can influence both binding and functional activity. - Keywords: nicotine; nicotine receptor; drug discrimination; antinociception.